{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:04:12Z","timestamp":1768287852111,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Stereotactic radiosurgery (SRS) has become a standard approach for the treatment of patients with few metastatic brain lesions. However, the optimal treatment approach for the use radiotherapy in the treatment of non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) remain unclear. This study aimed to compare the survival outcomes and intracranial local control in NSCLC patients with 1\u20134 BMs who are treated with SRS using linear accelerators (LINAC-SRS), whole-brain radiotherapy (WBRT), or WBRT plus radiotherapy boost (WBRT\u2009+\u2009RTB).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We retrospectively analyzed 156 NSCLC patients with 1\u20134 BMs who received LINAC-SRS, WBRT, and WBRT\u2009+\u2009RTB. The median overall survival (OS), intracranial progression-free survival (iPFS), and distant brain failure-free survival (DBF-FS) and related prognostic factors were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up period was 31.6\u00a0months. The median OS times in the LINAC-SRS, WBRT, and WBRT\u2009+\u2009RTB groups were not reached, 33.3\u00a0months and 27.9\u00a0months, respectively. The difference in survival rate was non-significant (<jats:italic>P<\/jats:italic>\u2009=\u20090.909). The 2-year iPFS and DBF-FS rates in the LINAC-SRS, WBRT and WBRT\u2009+\u2009RTB groups were 51.6% and 37.5%; 42.0% and 50.4%; and 51.1% and 56.1%, respectively. There was no significant difference in 2-year iPFS or DBF-FS among the three groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.572 for iPFS<jats:italic>, P<\/jats:italic>\u2009=\u20090.628 for DBF-FS). Multivariate analysis showed that the independent adverse prognostic factors for OS, iPFS, and DBF-FS were neurological symptoms, recursive partitioning analysis (RPA) class, and targeted therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>LINAC-SRS did not result in significantly superior survival times or intracranial local control compared to WBRT or WBRT\u2009+\u2009RTB in the treatment of NSCLC patients with 1\u20134 BMs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10083-8","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T07:02:49Z","timestamp":1664002969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1\u20134 brain metastases"],"prefix":"10.1186","volume":"22","author":[{"given":"Zhengting","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoxiong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"issue":"3","key":"10083_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10083_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","volume":"23","author":"N Lamba","year":"2021","unstructured":"Lamba N, Wen PY, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol. 2021;23(9):1447\u201356.","journal-title":"Neuro Oncol"},{"issue":"9","key":"10083_CR3","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/neuonc\/nos152","volume":"14","author":"FG Davis","year":"2012","unstructured":"Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 2012;14(9):1171\u20137.","journal-title":"Neuro Oncol"},{"issue":"4","key":"10083_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG, Deming R, Burri SH, et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. Jama-j am med assoc. 2016;316(4):401\u20139.","journal-title":"Jama-j am med assoc"},{"issue":"1","key":"10083_CR5","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S1470-2045(17)30692-7","volume":"19","author":"BM Alexander","year":"2018","unstructured":"Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, et al. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018;19(1):e33\u201342.","journal-title":"Lancet Oncol"},{"issue":"6","key":"10083_CR6","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16(6):e270\u20138.","journal-title":"Lancet Oncol"},{"key":"10083_CR7","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.2147\/CMAR.S203461","volume":"11","author":"F Lu","year":"2019","unstructured":"Lu F, Hou Y, Xia Y, Li L, Wang L, Cao K, Chen H, Chang L, Li W. Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis. Cancer Manag Res. 2019;11:4255\u201372.","journal-title":"Cancer Manag Res"},{"key":"10083_CR8","doi-asserted-by":"crossref","unstructured":"Lin B, Huang D, Du H, Fan J, Zhang Y, Feng G, et al. Whole-brain radiation therapy with simultaneous integrated boost versus whole-brain radiation therapy plus stereotactic radiosurgery for the treatment of brain metastasis from lung cancer. Front Oncol.\u00a02021:11(null):631422.","DOI":"10.3389\/fonc.2021.631422"},{"issue":"4","key":"10083_CR9","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.prro.2017.01.001","volume":"7","author":"JA Miller","year":"2017","unstructured":"Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Suh JH, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Chao ST. The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases. Pract radiat oncol. 2017;7(4):e263\u201373.","journal-title":"Pract radiat oncol"},{"issue":"2","key":"10083_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ijrobp.2021.09.003","volume":"112","author":"S Myrehaug","year":"2022","unstructured":"Myrehaug S, Hudson J, Soliman H, Ruschin M, Tseng CL, Detsky J, Husain Z, Keith J, Atenafu EG, Maralani P, et al. Hypofractionated Stereotactic Radiation Therapy for Intact Brain Metastases in 5 Daily Fractions: Effect of Dose on Treatment Response. Int j radiat oncol. 2022;112(2):342\u201350.","journal-title":"Int j radiat oncol"},{"issue":"8","key":"10083_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial. Lancet oncol. 2017;18(8):1049\u201360.","journal-title":"Lancet oncol"},{"issue":"11","key":"10083_CR12","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","volume":"10","author":"EL Chang","year":"2009","unstructured":"Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037\u201344.","journal-title":"Lancet Oncol"},{"issue":"1","key":"10083_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12885-016-2989-3","volume":"17","author":"D Rades","year":"2017","unstructured":"Rades D, Janssen S, Dziggel L, Blanck O, Bajrovic A, Veninga T, Schild SE. A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases. BMC Cancer. 2017;17(1):30.","journal-title":"BMC Cancer"},{"issue":"8","key":"10083_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1080\/0284186X.2021.1924399","volume":"60","author":"AT Karlsson","year":"2021","unstructured":"Karlsson AT, Hjermstad MJ, Omdahl T, Aass N, Skovlund E, Hellebust TP, Johansen S, Kaasa S, Yri OE. Overall survival after initial radiotherapy for brain metastases; a population based study of 2140 patients with non-small cell lung cancer. Acta oncol. 2021;60(8):1054\u201360.","journal-title":"Acta oncol"},{"key":"10083_CR15","doi-asserted-by":"publisher","first-page":"576700","DOI":"10.3389\/fonc.2020.576700","volume":"10","author":"M Ni","year":"2020","unstructured":"Ni M, Liu W, Jiang A, Wang Y, Sheng Y, Zeng H, Liu N, Li L, Qi Y, Wang Y, et al. Whole Brain Radiation Therapy Plus Focal Radiation Boost May Generate Better Survival Benefit for Brain Metastases From Non-small Cell Lung Cancer. Front Oncol. 2020;10:576700.","journal-title":"Front Oncol"},{"issue":"2","key":"10083_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","volume":"135","author":"M Ge","year":"2017","unstructured":"Ge M, Zhuang Y, Zhou X, Huang R, Liang X, Zhan Q. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J neuro-oncol. 2017;135(2):413\u20138.","journal-title":"J neuro-oncol"},{"issue":"5","key":"10083_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/ijc.33677","volume":"149","author":"X Yu","year":"2021","unstructured":"Yu X, Sheng J, Pan G, Fan Y. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Int j cancer. 2021;149(5):1121\u20138.","journal-title":"Int j cancer"},{"issue":"1","key":"10083_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1186\/s12885-019-6005-6","volume":"19","author":"Y Chen","year":"2019","unstructured":"Chen Y, Wei J, Cai J, Liu A. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis. BMC Cancer. 2019;19(1):793.","journal-title":"BMC Cancer"},{"issue":"1","key":"10083_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","volume":"17","author":"NJ Thomas","year":"2022","unstructured":"Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, Sinha S, Pollom EL, Nagpal S, Camidge DR, et al. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J thorac oncol. 2022;17(1):116\u201329.","journal-title":"J thorac oncol"},{"issue":"5","key":"10083_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jtho.2017.12.006","volume":"13","author":"TP Robin","year":"2018","unstructured":"Robin TP, Camidge DR, Stuhr K, Nath SK, Breeze RE, Pacheco JM, Liu AK, Gaspar LE, Purcell WT, Doebele RC, et al. Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer. J thorac oncol. 2018;13(5):715\u201320.","journal-title":"J thorac oncol"},{"issue":"2","key":"10083_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.radonc.2017.03.007","volume":"123","author":"MK Doherty","year":"2017","unstructured":"Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbe C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, et al. Treatment options for patients with brain metastases from EGFR\/ALK-driven lung cancer. Radiother Oncol. 2017;123(2):195\u2013202.","journal-title":"Radiother Oncol"},{"key":"10083_CR22","doi-asserted-by":"crossref","unstructured":"Matsunaga S, Shuto T. Outcomes of gamma knife radiosurgery for brain metastases from anaplastic lymphoma kinase rearrangement-positive and EGFR mutation-positive non-small cell lung cancer. Cureus.\u00a02021;13(12):e20398.","DOI":"10.7759\/cureus.20398"},{"issue":"16","key":"10083_CR23","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.3390\/cancers13164030","volume":"13","author":"CY Liao","year":"2021","unstructured":"Liao CY, Lee CC, Yang HC, Chen CJ, Chung WY, Wu HM, Guo WY, Liu RS, Lu CF. Enhancement of Radiosurgical Treatment Outcome Prediction Using MRI Radiomics in Patients with Non-Small Cell Lung Cancer Brain Metastases. Cancers (Basel). 2021;13(16):4030.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10083_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-021-02089-z","volume":"19","author":"S Zhao","year":"2021","unstructured":"Zhao S, Zhang Z, Zhan J, Zhao X, Chen X, Xiao L, Wu K, Ma Y, Li M, Yang Y, et al. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Med. 2021;19(1):223.","journal-title":"BMC Med"},{"issue":"19","key":"10083_CR25","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1002\/cncr.33085","volume":"126","author":"A Steindl","year":"2020","unstructured":"Steindl A, Yadavalli S, Gruber KA, Seiwald M, Gatterbauer B, Dieckmann K, Frischer JM, Klikovits T, Zochbauer-Muller S, Grisold A, et al. Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases. Cancer. 2020;126(19):4341\u201352.","journal-title":"Cancer"},{"issue":"5","key":"10083_CR26","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.ijrobp.2021.02.044","volume":"110","author":"O Arrieta","year":"2021","unstructured":"Arrieta O, Maldonado F, Turcott JG, Zatarain-Barr\u00f3n ZL, Barr\u00f3n F, Blake-Cerda M, Cabrera-Miranda LA, Cardona AF, de la Garza JG, Rosell R. Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized phase 2 Study (PRoT-BM trial). Int j radiat oncol. 2021;110(5):1442\u201350.","journal-title":"Int j radiat oncol"},{"issue":"4","key":"10083_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","volume":"12","author":"V Gondi","year":"2022","unstructured":"Gondi V, Bauman G, Bradfield L, Burri SH, Cabrera AR, Cunningham DA, Eaton BR, Hattangadi-Gluth JA, Kim MM, Kotecha R, et al. Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2022;12(4):265\u201382.","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"10083_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","volume":"29","author":"M Kocher","year":"2011","unstructured":"Kocher M, Soffietti R, Abacioglu U, Vill\u00e0 S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952\u201326001 study. J clin oncol. 2011;29(2):134\u201341.","journal-title":"J clin oncol"},{"issue":"2","key":"10083_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamaoncol.2018.4610","volume":"5","author":"TM Churilla","year":"2019","unstructured":"Churilla TM, Chowdhury IH, Handorf E, Collette L, Collette S, Dong Y, Alexander BM, Kocher M, Soffietti R, Claus EB, et al. Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial. Jama oncol. 2019;5(2):243\u20137.","journal-title":"Jama oncol"},{"issue":"4","key":"10083_CR30","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.21037\/apm-20-1203","volume":"9","author":"H Liu","year":"2020","unstructured":"Liu H, Xu X, Wang J, Wang W, Ma C, Sun T, Shao Q. Clinical study on different doses and fractionated radiotherapies for multiple brain metastases of non-EGFR mutant lung adenocarcinoma. Ann Palliat Med. 2020;9(4):2003\u201312.","journal-title":"Ann Palliat Med"},{"issue":"34","key":"10083_CR31","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","volume":"32","author":"V Gondi","year":"2014","unstructured":"Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810\u20136.","journal-title":"J Clin Oncol"},{"key":"10083_CR32","unstructured":"Guo T, Chu L, Chu X, Yang X, Li Y, Zhou Y, Xu D, Zhang J, Wang S, Hu J et al: Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors. (2218\u20136751 (Print))."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10083-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10083-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10083-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T07:07:50Z","timestamp":1664003270000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10083-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10083"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10083-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,24]]},"assertion":[{"value":"12 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. The Third Affiliated Hospital of Kunming Medical University Research Ethics Committee has confirmed that no ethical approval is required. Informed consent was waived by the committee because of the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to particiate"}},{"value":"Informed consent was waived by the committee because of the retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1010"}}